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Pharmacologically Antagonizing the CXCR4-CXCL12
Chemokine Pathway with AMD3100 Inhibits
Sunlight-Induced Skin Cancer
Seri N.E. Sarchio1,2,3,4, Richard A. Scolyer5,6,7, Clare Beaugie1,2,3, David McDonald1,2,3,8,
Felix Marsh-Wakefield1,2,3, Gary M. Halliday2,3 and Scott N. Byrne1,2,3
One way sunlight causes skin cancer is by suppressing anti-tumor immunity. A major mechanism involves
altering mast cell migration via the C-X-C motif chemokine receptor 4–C-X-C motif chemokine ligand 12 (CXCR4-
CXCL12) chemokine pathway. We have discovered that pharmacologically blocking this pathway with the CXCR4
antagonist AMD3100 prevents both UV radiation-induced immune suppression and skin cancer. The majority of
control mice receiving UV-only developed histopathologically confirmed squamous cell carcinomas. In contrast,
skin tumor incidence and burden was significantly lower in AMD3100-treated mice. Perhaps most striking was
that AMD3100 completely prevented the outgrowth of latent tumors that occurred once UV irradiation ceased.
AMD3100 protection from UV immunosuppression and skin cancer was associated with reduced mast cell
infiltration into the skin, draining lymph nodes, and the tumor itself. Thus a major target of CXCR4 antagonism
was the mast cell. Our results indicate that interfering with UV-induced CXCL12 by antagonizing CXCR4
significantly inhibits skin tumor development by blocking UV-induced effects on mast cells. Hence, the CXCR4-
CXCL12 chemokine pathway is a novel therapeutic target in the prevention of UV-induced skin cancer.
Journal of Investigative Dermatology (2013) 134, 1091–1100; doi:10.1038/jid.2013.424; published online 14 November 2013
INTRODUCTION
The UV wavelengths in sunlight are the prime etiological cause
of skin cancer. Despite widespread community awareness of
the need for protection from exposure to UV, the incidence of
both melanoma and non-melanoma skin cancer continues to
rise. For some patients, including those with severe UV skin
damage and some solid organ transplant recipients and other
immunosuppressed patients, this may lead to the occurrence of
many highly aggressive metastatic skin cancers (Moloney et al.,
2006; Lott et al., 2010). Rationale development of novel
preventative and therapeutic treatment options for these high-
risk patients requires an understanding of how UV causes skin
cancer. Sunlight-induced genetic damage and suppression of
the anti-tumor immune response are both causative for skin
cancer. Protection of either of these could reduce skin cancer
incidence, particularly in high-risk individuals. Although the
mechanisms of UV-induced DNA damage have been the topics
of concerted research efforts, the cellular and molecular
mechanisms underlying UV-induced immune suppression are
less well understood. Therapeutically targeting both the DNA
damaging and immune-suppressive effects of UV will be
required to successfully prevent and treat aggressive skin
cancers. To that end, we have identified the C-X-C motif
chemokine receptor 4–C-X-C motif chemokine ligand 12
(CXCR4-CXCL12) chemokine pathway as critical to the ability
of UV to suppress anti-tumor immunity and cause skin cancer.
The CXCR4-CXCL12 chemokine axis is involved, either
directly or indirectly, in the growth and metastasis of a number
of different tumors, including those of the breast (Mu¨ller et al.,
2001), esophagus (Kaifi et al., 2005), colon (Kim et al., 2005),
ovaries (Scotton et al., 2002), and skin (Mu¨ller et al., 2001;
Murakami et al., 2002; Chen et al., 2006; Basile et al., 2008).
For metastatic melanoma (Scala et al., 2005) and aggressive
non-melanoma skin cancers in particular (Basile et al., 2008),
high CXCR4 correlates with poor prognostic outcomes. We
previously demonstrated that exposure to UV affects the
migration of dermal mast cells by altering the CXCR4-
CXCL12 chemokine axis (Byrne et al., 2008). Blocking
CXCR4þ cutaneous mast cell trafficking to the lymph nodes
using the novel CXCR4-antagonist AMD3100 (brand names
Mozobil and Plerixafor) revealed the requirement of this
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migration for UV suppression of T-cell-mediated immunity
(Byrne et al., 2008). In this study, we demonstrate that
pharmacologically antagonizing CXCR4 using AMD3100 also
protects from the development of UV-induced squamous cell
carcinoma (SCC). One mechanism involves protection from
UV-induced immune suppression by interfering with the ability
of UV to recruit mast cells to the dermis and draining lymph
nodes as well as into the tumor itself.
RESULTS
AMD3100 protects from the development of UV-induced SCC
Although CXCR4 has been implicated in the growth and
metastasis of a number of different cancer types, its role in the
growth of primary UV-induced skin cancers is unknown.
Pharmacological treatment with AMD3100 significantly
reduced the number of mice that developed UV-induced skin
cancer (Figure 1a, c, and d) and the number of tumors that
arose on tumor-bearing mice (Figure 1b and c). Although new
tumors continued to appear at regular intervals in UV-
irradiated mice that did not receive drug, no new tumors
appeared in mice treated with AMD3100 after UV cessation at
week 30 (Figure 1a). All of the UV-induced tumors were
histologically confirmed as SCCs (Figure 1e and f). Of the five
tumors that developed in four AMD3100-treated mice, all
were either moderately (60%) or well- (40%) differentiated
SCCs. In contrast, 10% of tumors in the UV-only group were
poorly differentiated SCCs. The remainder were moderately
(63%) or well- (27%) differentiated SCCs.
Staining of these SCCs for CXCR4 revealed that the tumors
arising on control, untreated mice expressed significantly
higher levels of CXCR4 compared with AMD3100-treated
mice (Supplementary Figure S1a and S1b online). There was
a trend for more aggressive SCCs to express higher CXCR4
levels, but due to the low numbers of poorly differentiated
tumors that developed this did not reach statistical significance
(Supplementary Figure S1b online).
AMD3100 inhibits mast cell accumulation into UV-induced
SCCs and tumor-draining lymph nodes
We previously described a role for the CXCR4-CXCL12
chemokine pathway in directing the traffic of mast cells to
and from skin exposed to a single dose of UV (Byrne et al.,
2008). An increasing awareness of the pro-tumorigenic role
mast cells can have in skin cancer development (Ch’ng et al.,
2006; Sarchio et al., 2012) led us to investigate whether
AMD3100 was protecting from UV-induced skin cancer
by affecting mast cell migration. SCCs from untreated
UV-exposed mice (Figure 2a and c) contained significantly
greater numbers of mast cells than those that arose on
AMD3100-treated mice (Figure 2b and c). In tumor-bearing
AMD3100-treated mice, the majority of mast cells were
confined to surrounding stroma with few mast cells found
within the tumor itself (Figure 2b). In contrast, UV-exposed
mice not receiving AMD3100 had significant numbers of mast
cells infiltrating both the stroma and the tumor itself
(Figure 2a). A statistically significant positive correlation
existed between the density of mast cells inside the SCCs
and tumor grade (Figure 2d).
The density of mast cells within tumor-draining lymph
nodes was not statistically different between those few mice
that developed tumors despite receiving AMD3100 (56 (33–
72) cells per mm2) compared with mice without the drug (46
(31–69) cells per mm2). Lymph nodes from unirradiated mice
contained significantly fewer mast cells than the UV-exposed,
tumor-bearing mice, and this was not altered by AMD3100
(Figure 2g). However, the distribution of mast cells within
these nodes was dramatically different (Figure 2e and f). Mast
cells in AMD3100-treated UV-exposed mice (Figure 2f) were
restricted to the paracortical region of the lymph node. Very
few mast cells were found further than 300mm from the
capsule (i.e., in the medullary region). In contrast, control
tumor-bearing mice were infiltrated with significantly larger
numbers of mast cells deep within the tumor-draining lymph
nodes (along medullary cords and into the T-cell zones;
Figure 2e and g). Cytokeratin-positive staining was also
observed in this location (Figure 2h), suggesting that these
lymph nodes contained micro-metastases or cell material
originating from the cutaneous SCCs. Moreover, toluidine
blue–staining mast cells and cytokeratin positivity were often
found in the same lymph node location (Figure 2i). A
statistically significant positive correlation existed between
the number of cytokeratin-positive foci in tumor-draining
lymph nodes and tumor grade (Figure 2j).
AMD3100 interferes with UV modulation of mast cell migratory
responses
Our results to this point suggested that AMD3100 protects
from UV-induced tumor formation by interfering with the
ability of UV to recruit mast cells to the skin and draining
lymph nodes. To determine whether this was the case, we first
verified that our chronic UV regime resulted in an accumula-
tion of mast cells at the site of UV exposure. Between 11 and
16 weeks of UV is sufficient to observe a significant accumu-
lation of dermal mast cells at the site of UV exposure
(Figure 3a). Upregulation of CXCL12 at the dermal–
epidermal junction occurred at this time (Figure 3b). Blocking
CXCR4 prevented mast cells from infiltrating the superficial
dermal layer of UV-exposed skin (Figure 4a–f) but not mast
cell infiltration of the deep dermal layer and sub-cutis.
AMD3100 treatment also prevented UV-induced mast cell
accumulation in skin-draining lymph nodes (Figure 4g) but not
the spleen (Figure 4h). These results suggest that while
exposure to chronic UV results in an accumulation of mast
cells in the spleen, another chemokine pathway is involved in
their recruitment into this secondary lymphoid organ.
To determine whether the protective effects of AMD3100
were long lasting, a drug withdrawal experiment was per-
formed. The results clearly show that withdrawing oral
AMD3100 even for a short period of time (a few days) is
enough for the pharmacological effect of CXCR4 antagonism
to dissipate (Supplementary Figure S2 online). This suggests
that for oral AMD3100 to have any long-term therapeutic
benefit against the damaging effects of UV, it would need to
be continually supplied.
Similar to mast cells, tumor-infiltrating FoxP3þ regulatory
T cells express CXCR4 (Wei et al., 2007), are induced by UV
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(Gorman et al., 2007), and have been associated with the
growth of SCCs (Clark et al., 2008). Exposure to chronic UV
resulted in an increase of FoxP3þ cells at the irradiated site;
however, unlike its effects on mast cells, AMD3100 did not
suppress this accumulation (Supplementary Figure S3a online).
CXCR4 is also expressed by endothelial (Zheng et al., 2007)
and non-endothelial hematopoietic progenitor cells (Jin et al.,
2006). These Sca-1-expressing circulating progenitors are
recruited to sites of injury via a CXCL12 gradient and are
involved in angiogenesis and revascularization. To determine
whether AMD3100 was protecting from UV-induced skin
cancer development by preventing the formation of new
tumor-supportive blood vessels, we stained for Sca-1.
However, exposure to 16-weeks UV reduced the expression
of Sca-1 in the skin (Supplementary Figure S3b online), which
was unaffected by AMD3100 treatment. Another possibility is
that upregulation of CXCL12 in chronically UV-exposed skin
promotes the phenoconversion of CXCR4þ dermal fibroblasts
into pro-tumorigenic myofibroblasts (Gharaee-Kermani et al.,
2012). Alternatively, mast cells recruited to the skin by UV
may influence the differentiation and function of dermal
myofibroblasts (Gailit et al., 2001). These CXCL12-secreting
‘‘cancer-associated fibroblasts’’ (Orimo et al., 2005) express
alpha-smooth muscle actin (a-SMA) and are found within the
stroma of both melanoma (Tsukamoto et al., 1992) and
non-melanoma skin cancers (Kacar et al., 2012). We have
discovered that exposure to UV increases the number of
a-SMAþ cells in the skin (Supplementary Figure S3c online).
However, these cells are not the target of AMD3100 therapy
as mice receiving the CXCR4 antagonist showed no significant
difference in the number of dermal myofibroblasts
(Supplementary Figure S3c online). The only target of
AMD3100 therapy that we could find is a mast cell.
Next, to confirm that AMD3100 was blocking the recruit-
ment of mast cells into chronically UV-exposed skin rather
than inducing local proliferation, we transferred carboxyfluor-
escein-diacetate succinimidyl ester (CFSE)-labeled bone
marrow–derived mast cells into mice that had previously
received 16 weeks of chronic UV. A significantly larger
number of CFSEþ mast cells were recruited into the skin of
mice that had received UV only compared with unirradiated
mice. All mice in the UV group had at least one mast cell
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Figure 1. AMD3100 protects from UV-induced squamous cell carcinomas (SCCs). (a) 9–11 C57BL/6 mice were UV-exposed for 30 weeks with (K) or without
(J) AMD3100 in their water. Tumor development was monitored for 10 more weeks with AMD3100 throughout. Unirradiated mice with (&) or without (’)
AMD3100 did not develop SCCs. Median tumor size and growth rates for controls (3.5 (2–5.5) and 0.8665 (0.3715–1.500)mm per week) were not statistically
different from tumors arising on AMD3100-treated mice (6.5 (4.25–8.25)mm per week; P¼0.1032 and 0.9261 (0.5209–1.066)mm per week; P¼0.5934,
respectively). (b) Tumor multiplicity shown as average number of tumors per mouseþ SEM (two-way analysis of variance). (c, d) Clinical photos showing SCCs,
bar¼ 1cm. Hematoxylin and eosin of UV-induced SCCs from (e) controls or (f) AMD3100-treated mice were histopathologically confirmed as SCCs. Bar¼ 500mm.
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per section. Very few mast cells found their way into control,
unexposed skin. Indeed, 9 of the 15 mice (60%) in this group
had no detectable CFSEþ mast cells in any skin section
analyzed (Supplementary Figure S3d online). Treatment with
AMD3100 for 72 hours before the adoptive transfer signifi-
cantly reduced mast cell recruitment into UV-exposed skin
(Supplementary Figure S3d online). No fluorescently labeled
mast cells were detectable in skin-draining lymph nodes at this
early time point, suggesting that mast cells traffic there later
via the skin.
AMD3100 prevents chronic UV-induced immune suppression
To determine whether AMD3100 treatment of our chronically
UV-irradiated mice prevented systemic immune suppression,
another group of mice were exposed to 16 weeks of UV
before being sensitized in the unirradiated abdomen to
ovalbumin (OVA). Exposure to chronic UV significantly
suppressed the induction of cell-mediated immunity
(Figure 5a), whereas mice that were treated with AMD3100
were significantly protected from this suppression (Figure 5a
and b). This was not due to alteration in the time course for the
delayed-type hypersensitivity (DTH) response as the same
result was observed when the DTH was measured at later
times (Figure 5b).
DISCUSSION
Pharmacologically targeting the CXCR4-CXCL12 chemokine
pathway is proving to be a promising new therapeutic strategy
that has the potential to interfere with tumor progression and
metastasis for many different tumor types. We have shown
that it is also highly effective at preventing the growth of UV-
induced SCCs. CXCR4 is highly expressed by a wide variety of
tumors and is associated with poor prognostic outcomes.
Exposure to 30 weeks of UV resulted in the formation and
progression of SCCs in the majority of control mice. In
contrast, almost 80% of mice receiving AMD3100 were tumor
free over the entire 40-week observation period. Moreover,
AMD3100 protected tumor-bearing mice from the develop-
ment of multiple UV-induced SCCs. When CXCR4 levels were
examined in SCCs that developed during photocarcinogenesis,
it was discovered that CXCR4 expression was significantly
higher in mice not treated with AMD3100. Indeed, the few
tumors that did arise in AMD3100-treated mice expressed
very low levels of CXCR4. This means that CXCR4 expression
is a key molecular marker expressed by UV-induced SCCs and
that treatment with AMD3100 prevents the outgrowth of
CXCR4high tumor cells. Similar to what has been shown in
other cancer models, our results suggest that CXCR4-expres-
sing cells in the skin are potentially a direct target of
AMD3100 therapy. Although this is likely to be a major way
in which AMD3100 prevents UV-induced skin cancer, pre-
cisely what effect AMD3100 has on CXCR4-expressing cells in
UV-exposed skin remains to be determined.
Perhaps most striking is that AMD3100 completely pre-
vented the outgrowth of latent tumors that occur once UV
irradiation ceased. This strongly indicates that AMD3100
possesses therapeutic potential for UV-induced skin cancer,
especially if used in conjunction with sun avoidance strategies
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Figure 2. AMD3100 prevents mast cell accumulation into squamous cell
carcinomas (SCCs) and lymph nodes. Tumor sections from (a) controls and
(b) AMD3100-treated mice were stained for mast cells and (c) counted.
Dotted line indicates the surface; solid line indicates boundary between tumor
(T) and stroma (S). Bar¼250mm. (d) Mast cell density in SCCs versus
tumor grade. Lymph node sections from tumor-bearing (e) controls,
(f) AMD3100-treated mice were stained for mast cells and (g) counted. Dotted
line indicates capsule. The red line is 300mm from the capsule. Bar¼2mm.
(h) Lymph node sections from SCC-bearing mice were stained for cytokeratin
(green). White line indicates capsule. (i) Lymph nodes were stained first for
cytokeratin, then for toluidine blue. Bar¼ 250mm. (j) Cytokeratin positivity
in SCC-draining nodes versus tumor grade.
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in high-risk individuals. Our investigation into the cellular and
molecular mechanisms involved revealed that exposure to
chronic doses of UV significantly upregulated cutaneous
expression of CXCL12. This chemokine ligand for CXCR4
was most highly expressed at the dermal–epidermal junction,
which was concurrent with infiltration by mast cells into the
superficial dermis. The two events are linked because blocking
the ability of CXCR4þ mast cells to migrate towards UV-
induced CXCL12 with AMD3100 significantly inhibited their
migration into the superficial dermis. Our experiment injecting
CFSE-labeled activated mast cells into mice determined that
recruitment, rather than local proliferation of mast cells, was
the primary mechanism by which sun-exposed dermis accu-
mulated large numbers of mast cells. Alternatively, AMD3100
potentially could induce mast cell apoptosis (Righi et al.,
2011). However, this is unlikely as we did not observe a
significant reduction in cutaneous mast cells in unirradiated
AMD3100-treated groups nor was there any reduction in
splenic mast cell density of UV-exposed, AMD3100-treated
mice. Interestingly, AMD3100 did not inhibit UV-induced
mast cell migration into the deep dermis and sub-cutis. This
suggests that recruitment of mast cell progenitors from the
blood into the skin occurs via a different chemokine pathway
that is not inhibited by AMD3100, potentially UV-induced
150
125
100
75
50
25
0
0
No UV versus UV linear regression: P = 0.0003
1 2 3
No UV
16 weeks of chronic UV
CXCL12
DAPI
CXCL12
DAPI
4 5 6 7 8 9 10 11 12 13 14 15 16
Time after commencement of chronic UV (weeks)
M
as
t c
el
l d
en
sit
y 
(ce
lls
 m
m–
2 )
NS
NS
NS
NS
NS
*
**
NS *
*
UV
No UV
P = 0.0325
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
No UV UV
Cu
ta
ne
ou
s 
CX
CL
12
 e
xp
re
ss
io
n 
(A
U)
Figure 3. Mast cells are recruited into C-X-C motif chemokine ligand 12 positive (CXCL12þ ) UV-exposed skin. (a) 16 Groups were entered into the same
UV exposure regime used for carcinogenesis. Weekly, beginning 1 week after UV, groups of mice (n¼ 3–6 per week) were examined for mast cell density in
UV-exposed back skin (K). Controls were not exposed to UV (J). Toluidine blue staining of 7-mm paraffin sections allowed for the determination of cutaneous
mast cell density. Mean±SEM shown. *Po0.05, **Po0.01 by a non-parametric Mann–Whitney U-test at individual time points. (b) Sections of skin from mice
exposed to 16 weeks of UV or not was stained for CXCL12 (green). Image analysis of CXCL12 in unirradiated controls (J), compared with UV-exposed skin
(K); non-parametric Mann–Whitney U-test. AU, arbitrary units; DAPI, 4,6-diamidino-2-phenylindole; NS, not significant.
SNE Sarchio et al.
Inhibiting UV-Induced Skin Cancer with AMD3100
www.jidonline.org 1095
stem cell factor (Kligman and Murphy, 1996) or CCL5 (Van
Nguyen et al., 2011) signaling via CCR1 and CCR4 (Juremalm
et al., 2002).
Mast cells have previously been observed in the stroma of
melanoma (Reed et al., 1996), basal cell carcinomas (Aoki
et al., 2003), and Merkel cell carcinomas (Beer et al., 2008). In
support of these observations, we found numerous mast cells
surrounding UV-induced SCCs. Additionally, mast cells were
found deep within control tumors themselves, particularly
poorly differentiated SCCs. There was a statistically significant
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Figure 4. AMD3100 blocks mast cell recruitment into the UV-exposed skin and draining lymph nodes but not spleen. Mice were UV-exposed for 16 weeks with
(d) AMD3100 (’) or (c) without AMD3100 (K) in their drinking water. Controls consisted of (a) unirradiated mice (J) and (b) those given AMD3100 only (&).
Sections of (a–f) skin, (g) draining lymph nodes, and (h) spleen were stained with toluidine blue, and the density of mast cells were enumerated. (a–d) Eosin
counterstaining allowed for differentiation between the epidermis (E), the superficial dermis (SD), and underlying deep dermis (DD). Bar¼ 500mm. Each point
represents a section from an individual mouse. The line indicates the median. Statistics were by one-way analysis of variance non-parametric Kruskal–Wallis test
with Dunn’s multiple comparisons. NS, not significant.
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positive correlation between the number of mast cells within a
tumor and tumor grade. In contrast, AMD3100-treated groups
had significantly fewer mast cells inside the tumor mass. UV-
induced mast cell recruitment to the superficial dermis as
well as the developing tumor is likely to have a profound
effect on the cutaneous tumor microenvironment as mast
cells produce a wide variety of pro-tumorigenic and immune-
suppressive compounds, including VEGF (vascular endothelial
growth factor), MMP-9 (matrix metalloproteinase 9), TGFb
(transforming growth factor-b), and IL-10 (Ch’ng et al., 2006;
Sarchio et al., 2012). Indeed, high mast cell densities in
human skin correlates with susceptibility to both melanoma
(Grimbaldeston et al., 2004) and basal cell carcinoma
(Grimbaldeston et al., 2000). Taken together, this suggests that
mast cells are important for the development of UV-induced skin
tumors and that preventing their accumulation into UV-exposed
skin is likely to have an impact on the incidence of skin cancer.
We have confirmed this by showing that pharmacologically
blocking mast cell accumulation into the upper dermis with
AMD3100 averts the development of UV-induced skin cancer.
Although it is clear from our results that a major mechanism
by which AMD3100 protects from UV-induced skin cancer is
by inhibiting mast cell migration, it is likely that AMD3100 is
also targeting other cells and pathways. There was no
inhibitory effect of AMD3100 on UV-induced recruitment of
FoxP3þ regulatory T cells into the skin. However, this does
not rule out a role for AMD3100 further inhibiting the
migration of these regulatory cells after they have entered
the skin. It also does not exclude the possibility that other UV
regulatory cells are being inhibited by AMD3100, including B
cells (Byrne et al. 2008), type 1 regulatory T cells (Toda et al.
2011), natural killer T cells (Moodycliffe et al. 2000), or
macrophages (Toichi et al. 2008). Molecular targets of
AMD3100 protection from UV-induced immune suppression
and carcinogenesis could include inhibition of TGFb and
tumor necrosis factor upregulation (Kim et al. 2012) or
blocking the activation of the Hedgehog pathway to prevent
epithelial–mesenchymal transition (Li et al. 2012).
AMD3100 is being used in Phase III clinical trials to
enhance G-CSF mobilization of bone marrow stem cells
before autologous stem-cell transplantation (DiPersio et al.,
2009). In mice, subcutaneous injection with 250mg AMD3100
alone also leads to a rapid increase in peripheral white blood
cell numbers (Juarez et al., 2012). However, we saw no
significant change in blood leukocyte counts of mice treated
orally with low, continuous doses of AMD3100. Our with-
drawal experiments indicated that oral AMD3100 needs to be
continuously supplied for maintenance of protection from UV
exposure. It will be interesting to determine in future experi-
ments whether the withdrawal or introduction of AMD3100
after 30 weeks of chronic UV leads to tumor development or
prevention, respectively. Apart from the inhibition of mast cell
migration and prevention of skin cancer, no other drug
complications were observed. This, together with the fact
that oral AMD3100 is less bioavailable (Murakami et al.,
2009), suggests that this route of drug administration is
effective in antagonizing CXCR4þ cells trafficking in the
blood and peripheral tissues but not sufficiently high enough
to affect the mobilization of bone marrow stem cells.
Close examination of skin-tumor draining lymph nodes
showed that they too were heavily infiltrated by many mast
cells. In AMD3100-treated mice, the mast cells were mostly
confined to the paracortical area. In contrast, mast cells
infiltrated the deep lymph node medullary cords of tumor-
bearing mice. CXCL12 is highly expressed by high endothelial
venules within the medullary cords (Okada et al., 2002),
which may explain why mast cells are attracted to this area.
One outcome of infiltration into lymph node T-cell zones by
mast cells could be the promotion of immune evasion by
suppressing T-cell-driven immunity (Byrne et al., 2008;
Chaco´n-Salinas et al., 2011) and/or modulating the activity
of regulatory cells (Lu et al., 2006). Another possibility is that
similar to what has been shown with other bone marrow–
derived cells (Kaplan et al., 2005), mast cells are involved
in the establishment of a UV-initiated CXCR4-driven
pre-metastatic niche in local tumor-draining lymph nodes.
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non-parametric Kruskal–Wallis test with Dunn’s multiple comparisons of the indicated groups). Individual mice and median are shown. (b) Changes in footpad
thickness were measured over 72hours. Percentage of immunosuppression was calculated by comparing the UV-exposed groups with their relevant unirradiated
controls. Repeated measures ordinary two-way ANOVA comparing UV-exposed mice with (K) or without AMD3100 (J); P¼ 0.0010. n¼5;
median±interquartile range shown. Uncorrected Fisher’s least significant difference multiple-comparison test at the individual time points. NS, not significant.
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This would be supported by our discovery that lymph nodes
draining UV-induced SCCs contained numerous cytokeratinþ
micro-metastases, often in close proximity to mast cells.
We have previously shown in an acute UV model that
blocking mast cell migration to the skin-draining lymph nodes
prevents UV-induced immune suppression (Byrne et al.,
2008). Here, we have extended these findings to show using
a DTH model that exposure to chronic UV also suppresses
T-cell-driven immunity and that AMD3100 treatment prevents
this suppression. This is likely to be a key mechanism by
which AMD3100 affords protection from SCC development,
because immune suppression is required for tumor
development (Kripke and Fisher, 1976).
UV-induced skin cancer is a growing clinical and economic
problem. For some patients, such as solid organ transplant
recipients, UV-induced metastatic SCCs is particularly aggres-
sive (Lott et al., 2010) with extremely poor prognostic outcomes
(Carucci, 2004). SCCs in these patients are not only more
numerous (Moloney et al., 2006) but are also significantly more
likely to metastasize (Martinez et al., 2003). The successful
prevention and treatment of aggressive UV-induced skin
cancers will therefore require equally aggressive therapeutic
interventions and prevention strategies. Our study reveals the
CXCR4-CXCL12 chemokine axis as a key molecular pathway
in the development of UV-induced skin cancer. Our
demonstration that the CXCR4 antagonist AMD3100 can
prevent UV-induced SCCs by selectively interfering with UV
modulation of mast cell migration highlights the therapeutic
potential of antagonizing this chemokine axis.
MATERIALS AND METHODS
AMD3100 treatment
AMD3100-treated female C57BL/6 mice (Animal Resource Centre;
Perth, Australia) were supplied 60mgml 1 AMD3100 (Sigma-
Aldrich; St Louis, MO) in their drinking water (Byrne et al., 2008).
For most experiments, AMD3100 commenced 7 days before the first
UV irradiation and was continued throughout the UV regime. All
experiments were approved by The University of Sydney animal
ethics committee (K14/4/4-2008/3/4779).
UV Exposure and tumor monitoring
Mice were shaved and exposed 4 daysweek 1 with increasing doses
of UVB: 50 (week 1), 75 (week 2), 100 (week 3), 150 (week 4), 200
(week 5), and finally 250mJcm 2 (weeks 6–30). This final dose is
below that which causes barely detectable sunburn in C57BL/6 mice
(Byrne et al., 2002). Location, size, and clinical appearance of each
tumor were monitored twice a week from the first tumor appearance
as we have described (Halliday et al., 2012).
DTH response
Three days after the last UV, the left and right abdominal flanks were
injected subcutaneously with 60mg OVA (Sigma-Aldrich) dissolved in
50ml saline containing 20mg Quil A (Saponin, Sigma-Aldrich) as we
have described (Byrne et al., 2006). Controls were injected with
saline containing Quil A but no OVA. AMD3100-supplemented
water was replaced with normal drinking water at immunization.
Seven days after sensitization, all mice were challenged by
subcutaneous injection into hind footpads with 30ml saline
containing 2% heat-aggregated OVA (HOVA). Then, at 0, 24, 48,
and 72hours after HOVA challenge, the thickness of the footpads
were measured with a spring-loaded micrometer (Mitutoyo,
Kawasaki, Japan). The change in footpad thickness was calculated
for each mouse. The increase in footpad thickness of unimmunized
control mice was subtracted from sensitized groups to give a measure
of the DTH.
Generation of activated CFSE-labeled bone marrow–derived
mast cells
Bone marrow stem cells were isolated from 6-week-old C57BL/6 mice
and cultured for 5 weeks at 106 cells per ml in complete RPMI
supplemented with 10ngml 1 murine rIL-3 (Peprotech, Rocky Hill,
NJ) and recombinant stem cell factor (Peprotech) to generate mast
cells. Activated CXCR4þ mast cells were generated by cross-linking
Fce receptors as we described (Byrne et al., 2008). In all, 107 mast
cells were then fluorescently labeled with 50mM CFSE (Molecular
Probes, Carlsbad, CA) before intravenous injection as we have
described (Rana et al., 2011) into one of the two groups: unirradi-
ated mice or groups that had previously been exposed to 16 weeks of
UV. Mice received either UV-only or were provided with AMD3100
in their drinking water 3 days before mast cell transfer. Forty-eight
hours later, the skin and draining lymph nodes were isolated and
assessed for the presence of CFSE-labeled cells by microscopy.
Histology and immunofluoresence
Sections (7mm) of the paraffin-embedded formalin-fixed tumor, skin,
lymph node, and spleen were stained with either hematoxylin and
eosin for histopathological analysis or with toluidine blue for mast cells.
Cutaneous mast cell numbers were calculated by dividing the number
of mast cells by the length of the skin section. Mast cell densities in the
tumors, surrounding stroma, lymph nodes, and spleen were calculated
by dividing the total number of mast cells by the area of each tissue
section.
Frozen skin, lymph node, and tumor sections (7mm) were fixed and
stained for either anti-CXCL12 (Peprotech) followed by chicken anti-
goat Alexa 488 (Molecular Probes), or anti-cytokeratin (Covance,
Emeryville, CA) followed by chicken anti-rabbit Alexa 488 (Molecular
Probes). Controls included normal goat or rabbit IgG. Sections were
finally mounted in DAPI (4,6-diamidino-2-phenylindole) containing
aqueous media (Vectorshield, Vector Laboratories, Burlingame, CA).
Mean CXCL12 gray intensities were quantitated and normalized to
control groups for statistical analysis.
Statistical analysis
Differences in skin tumor incidence between untreated and
AMD3100-treated groups was compared using a log-rank (Mantel–
Cox) test. Tumor multiplicity was assessed by two-way analysis of
variance. A non-parametric Mann–Whitney U-test was used for
comparisons between the two groups. A non-parametric Kruskal–
Wallis one-way analysis of variance with a Dunn’s multiple compar-
isons test was used for comparisons involving multiple groups. Exact P
values were determined using Prism 6.0b (Graphpad Software, La
Jolla, CA), with Po0.05 considered statistically significant. Median
with 25–75% (interquartile) ranges are cited.
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